Navigation Links
Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse
Date:7/23/2014

LONDON, July 23, 2014 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has filed an investigational new drug application ("IND") with respect to its naloxone-based opioid overdose reversal nasal spray. Lightlake also announced today that it has received an additional commitment from the National Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health ("NIH"), to fund a second study with respect to Lightlake's nasal spray. Lightlake, in collaboration with NIDA, previously commenced a clinical trial with respect to its nasal spray in September 2013.

Naloxone is an injectable medicine that can rapidly reverse the overdose of prescription and illicit opioids. Lightlake has been developing a naloxone nasal spray that could widely expand its availability and use in preventing opioid overdose deaths, a public health problem of epidemic proportion in the United States. In collaboration with NIDA, Lightlake will now evaluate its technology on a larger population, which will be a key step towards approval in the United States and other worldwide regions.

"We are extremely pleased that NIDA has continued its support of our opioid overdose reversal treatment," said Dr. Roger Crystal, CEO of Lightlake. "This support demonstrates NIDA's commitment of having an FDA approved intranasal naloxone nasal spray available to the public."

"NIDA's continued commitment to advancing our overdose reversal treatment reflects their confidence in the potential of our treatment," said Kevin Pollack, CFO of Lightlake. "We believe that our treatment can make a huge difference in addressing the overdose epidemic and save a significant number of lives, and NIDA's support plays a critical role in achieving our goals."

About Lightlake Therapeutics Inc.

Lightlake Therapeutics Inc., a biopharmaceutical company, is using its expertise in opioid antagonists to build a platform of innovative intranasal naloxone solutions to common addictions and related disorders. Lightlake is developing a treatment to reverse opioid overdoses, which have reached epidemic proportions in the United States. Lightlake has successfully completed a clinical trial for this treatment in collaboration with the National Institute on Drug Abuse, part of the National Institutes of Health. Lightlake also has successfully completed a Phase II clinical trial to treat Binge Eating Disorder. For more information please visit: http://www.lightlaketherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

Corporate Contact:
Lightlake Therapeutics Inc.
Dr. Roger Crystal, CEO
+44(0)203 617 8739
info@lightlaketherapeutics.com

Investor Relations Contact:
Booke and Company, Inc.
212-490-9095
admin@bookeandco.com


'/>"/>
SOURCE Lightlake Therapeutics Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Initial Data from Lightlake Therapeutics Joint Clinical Trial with NIDA Shows Nasal Delivery of Naloxone for Opioid Overdose as a Promising Treatment
2. Lightlake Therapeutics to Present at 6th Annual LD MICRO Conference
3. Lightlake Therapeutics Retains KCSA Strategic Communications as Corporate Communications Advisors
4. Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology
5. MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics
6. Echo Therapeutics to Present at the Noble Financial Capital Markets Tenth Annual Equity Conference
7. Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness
8. Echo Therapeutics Hires Product Development Management Executive
9. Cell Therapeutics Announces 2014 Outlook and Recent Drug Portfolio Progress
10. Halozyme Therapeutics Provides an Update on Anticipated Milestones for 2014 at the 32nd Annual J. P. Morgan Healthcare Conference
11. Lilly Announces Acquisition of CGRP Antibody for Migraine Prevention from Arteaus Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... -- Hearing protection devices refer to the barriers that ... inner ear. Hearing protection devices include earplugs, uniform attenuation ... for users exposed to noise levels of over 80 ... are inserted in the ear canal to protect the ... natural sound perception with the help of acoustic filters. ...
(Date:2/9/2016)... Calif. , Feb. 9, 2016  Increasingly, health ... monitoring their vital signs with wireless technology. With the ... can automate patient oversight and remotely detect problems before ... vital signs across in-hospital environments. the ... the United States . --> ...
(Date:2/9/2016)... new report "Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 - ... the North America continued to lead global ... translated into revenues worth US$ 16,907.3 million. ... Asia-Pacific , Latin America , ... anti-bacterial market is inclined towards North America ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... Center for Autism and Related ... autism spectrum disorder (ASD). Beginning Jan. 1, 2016, Medicaid is covering autism treatment ... is key to providing effective treatment for individuals with ASD. Now, over 1,800 ...
(Date:2/9/2016)... ... February 09, 2016 , ... Cirracore Enterprise Cloud, ... move workloads to the cloud. Cirracore provides a secure VMware® vCloud Air ... the Internet. Transformation Solutions (TSL Partners) provides a full range of services ...
(Date:2/9/2016)... ... ... Journal of Pain Research has published the commentary “ Terminology of chronic ... John F. Peppin says “Terminology matters, yet little attention has been paid to the ... pain’ and ‘chronic non-cancer pain’ are replete in the literature; however, the distinction here ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... therapy products, announced today the introduction of the newly designed, innovative shoulder wrap. ... and better cold therapy coverage for the injured arm and shoulder to promote ...
(Date:2/9/2016)... ... 2016 , ... Shark Finds and Kevin Harrington, and the Product Managers of AsSeenOnTV.pro ... is a newly patented product that has solved some of the basic problems golfers have ... morning dew or right after a rain shower, might understand the struggle of placing the ...
Breaking Medicine News(10 mins):